Filana Therapeutics is a biotechnology company focused on developing novel investigational therapies that modulate the filamin A protein for treating central nervous system disorders. The company's primary focus is on tuberous sclerosis complex (TSC)-related epilepsy and other conditions associated with filamin A dysregulation or overexpression. Headquartered in Austin, Texas, and founded in 1998, Filana Therapeutics operates in the clinical development stage, working to advance its pipeline of filamin A-targeted candidates. The company is actively addressing FDA feedback related to its TSC program and is committed to bringing new treatment options to patients with limited therapeutic alternatives. Filana Therapeutics operates with a lean operational structure, emphasizing capital efficiency while pursuing its mission to develop meaningful medicines for neurological disorders tied to filamin A dysfunction.